CGON Revenue Flow
Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
- 2026-06-30: Revenue including tax $1.16M; Research and development $54.66M; Operating expenses (m); Net income -$79.06M.
- 2026-03-31: Revenue including tax $1.08M; Research and development $43.73M; Operating expenses (m); Net income -$60.20M.
- 2025-12-31: Revenue including tax $2.32M*; Research and development $29.96M*; Operating expenses (m); Net income -$41.31M*.
- 2025-09-30: Revenue including tax $1.67M; Research and development $27.88M; Operating expenses (m); Net income -$43.81M.
Consolidation item
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Counterparty Name
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Product or service
Separate filed amounts; connecting flows are not established. Components and totals may overlap.
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown
Revenue and expense 3 month
| Period end | Revenue including tax | Research and development | Operating expenses | Net income |
|---|---|---|---|---|
| 2026-06-30 | $1.16M | $54.66M | (m) | -$79.06M |
| 2026-03-31 | $1.08M | $43.73M | (m) | -$60.20M |
| 2025-12-31 | $2.32M* | $29.96M* | (m) | -$41.31M* |
| 2025-09-30 | $1.67M | $27.88M | (m) | -$43.81M |
| 2025-06-30 | $0.00 | $31.33M | $48.74M | -$41.43M |
| 2025-03-31 | $52.00K | $27.47M | $42.26M | -$34.45M |
| 2024-12-31 | (m) | (m) | $38.51M* | (m) |
| 2024-09-30 | $43.00K | $19.62M | $28.34M | -$20.41M |
| 2024-06-30 | $111.00K | $18.47M | $25.96M | -$18.90M |
| 2024-03-31 | $529.00K | $17.21M | $23.00M | -$16.93M |
| 2023-09-30 | $9.00K | $11.73M | $14.05M | -$11.77M |
| 2023-06-30 | $0.00 | $9.83M | $12.33M | -$11.61M |
| 2023-03-31 | $194.00K | $7.84M | $9.91M | -$8.67M |
Revenue and expense 6 month
| Period end | Revenue including tax | Research and development | Operating expenses | Net income |
|---|---|---|---|---|
| 2026-06-30 | $2.24M | $98.39M | (m) | -$139.26M |
| 2025-06-30 | $52.00K | $58.80M | $91.00M | -$75.88M |
| 2024-06-30 | $640.00K | $35.68M | $48.96M | -$35.84M |
| 2023-06-30 | $194.00K | $17.68M | $22.25M | -$20.28M |
Revenue and expense 9 month
| Period end | Revenue including tax | Research and development | Operating expenses | Net income |
|---|---|---|---|---|
| 2025-09-30 | $1.72M | $86.68M | (m) | -$119.69M |
| 2024-09-30 | $683.00K | $55.30M | $77.30M | -$56.24M |
| 2023-09-30 | $203.00K | $29.41M | $36.30M | -$32.05M |
Revenue and expense 12 month
| Period end | Revenue including tax | Research and development | Operating expenses | Income tax | Net income |
|---|---|---|---|---|---|
| 2025-12-31 | $4.04M | $116.64M | (m) | -$270.00K | -$161.00M |
| 2024-12-31 | $1.14M | $82.10M | $115.81M | $1.00K | -$88.04M |
| 2023-12-31 | $204.00K | $45.75M | $55.65M | $1.00K | -$48.61M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |